Australia markets closed

AusCann Group Holdings Ltd (AC8.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.04000.0000 (0.00%)
At close: 04:10PM AEST

AusCann Group Holdings Ltd

1202 Hay Street
Level 5
West Perth, WA 6005
Australia
61 8 6305 0705
https://auscann.com.au

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

NameTitlePayExercisedYear born
Mr. Christopher Mews A.C.I.S., B. Bus, C.P.A.Chief Financial Officer122.75kN/AN/A
Ms. Rachel Jelleff KerrCompany SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. AusCann Group Holdings Ltd is based in West Perth, Australia.

Corporate governance

AusCann Group Holdings Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.